In March 2013 the government had a chance to appeal its landmark loss in the Second Circuit in US v Caronia, the Ninth Circuit affirmed the conviction in US v. Harkonen, discussed below, and it settled two cases involving PAR Pharmaceuticals, one for off-label promotion and PAR’s action seeking to dismantle FDA regulation of marketing for approved products. See More...
|